Core Viewpoint - Kunshi Biotech has successfully completed a Series A financing round of 50 million RMB to advance its leading macrophage drug research and clinical transformation, particularly focusing on its third-generation CAR-M targeting HER2 pipeline and preclinical studies for pancreatic and lung cancers [1] Group 1: Financing and Development - The recent financing will primarily support the construction of the company's leading macrophage drug platform and accelerate the IND application and phase I clinical progress of its self-developed third-generation CAR-M targeting HER2 pipeline [1] - The successful completion of this financing reflects the capital market's high recognition of the company's innovation capabilities and research progress in the macrophage drug field [1] Group 2: Technological Innovations - Kunshi Biotech has developed four unique technological platforms that address core challenges in the autologous CAR-M therapy, including low transduction efficiency, high costs, long cycles, and weak anti-tumor capabilities [2] - The company's proprietary macrophage-specific viral modification technology has improved the transduction efficiency of adenoviruses and lentiviruses to over 90%, solving the industry's low gene delivery efficiency issue [3] - The third-generation CAR-M developed by Kunshi is the first of its kind globally, incorporating cytokines necessary for the autologous proliferation and activation of macrophages, promoting long-term survival and altering the tumor microenvironment [4] Group 3: Clinical Progress and Efficacy - Kunshi Biotech has established multiple preclinical pipelines targeting major diseases such as solid tumors and chronic diseases, with the RR-M01 pipeline for HER2-positive solid tumors showing promising safety and preliminary efficacy [6] - The RR-M01 injection has demonstrated good safety and encouraging preliminary efficacy in advanced solid tumor patients who were ineffective or intolerant to DS-8201 (trastuzumab deruxtecan), achieving a disease control rate (DCR) of 71.4% [7] - The first subject treated with a single dose of RR-M01 in December 2023 has achieved a progression-free survival (PFS) of 23 months without any other anti-tumor treatment, indicating long-term and high-quality disease control [8] Group 4: Company Vision and Future Plans - The founder of Kunshi Biotech expressed gratitude to shareholders for their support, emphasizing that this financing is a key milestone for the company's development [10] - The company aims to focus on the frontier of macrophage drugs, tackle the core challenges in solid tumor treatment, and push for the commercialization of innovative therapies that are safe, effective, and accessible to cancer patients [10]

Financing Activities - 修实生物医药 completed nearly 100 million RMB Series A financing, focusing on overseas market expansion and R&D investment in peptide synthesis [2] - 百达信生物 successfully raised over 30 million RMB in Pre-A financing to accelerate the construction of a GMP production base for vaccine adjuvants [2] - 迈锐迪 announced the completion of several million RMB angel round financing to develop nuclear medicine projects [3] - 星动纪元 completed nearly 1 billion RMB A+ round financing, focusing on embodied intelligence technology [3] - 蓝点触控 secured over 100 million RMB in C round financing to enhance robot control technology [4] - 鲲石生物 raised 50 million RMB in Series A financing to advance macrophage drug innovation [5] - RockFlow completed several million USD in new financing led by Ant Group, focusing on AI-driven fintech solutions [5] - 中凯信网络 raised 8 million RMB in angel round financing to enhance AI technology integration [6] - 比利信息 completed several million RMB A+ round financing to accelerate the development of a new media platform for the travel industry [6] - 易思旋磁 secured several million RMB in seed round financing to support early-stage R&D in magnetic technology [6] - 融和医疗 completed nearly 100 million RMB in B round financing to promote innovative treatments for chronic obstructive pulmonary disease [7] - 爱鸥光学 raised several million RMB A+ round financing to enhance product development in the optical field [7] - 星尘智能 completed several hundred million RMB A++ round financing, focusing on AI robotics technology [8] - 中合基因 raised several million RMB Pre-A+ round financing to accelerate the commercialization of green DNA synthesis equipment [8] - 商汤医疗 completed several hundred million RMB in strategic financing to enhance medical AI models [9] - 博思芯宇 secured several million RMB angel+ round financing to develop sustainable computing solutions [9] - 灵宇宙 completed 200 million RMB Pre-A round financing to advance AI and consumer robotics [10] - 加速进化 completed over 100 million RMB financing to enhance humanoid robotics development [10] - 基流科技 raised nearly 100 million RMB in B round financing to strengthen AI computing cluster technology [11] - 耀石锂电 completed A round financing to accelerate solid-state battery technology commercialization [12] - 广汽高域 completed 200 million RMB Pre-A round financing to advance flying car technology [12] Investment Funds - 杭州热电 plans to invest 200 million RMB in establishing an industrial investment fund [14] - 恩威医药 announced a 20 million RMB investment in a joint fund focusing on early-stage enterprises [14] - 广东省人工智能与机器人产业投资基金 was established with a total investment of 1 billion RMB [14] - 杭州润苗基金 launched with an initial scale of 2 billion RMB, focusing on early-stage tech startups [14] - 安徽海螺新兴产业股权投资基金 was established with a total investment of 1 billion RMB [14] - 湖南高速 established a 6.5 billion RMB infrastructure investment fund [14] - 农银投资 and 浦东创投 launched a 3.334 billion RMB private equity fund [14] - 烟台夹河幸福新城城市发展母基金 was established with a total investment of 1 billion RMB [14] - 上海中移数字转型私募基金 increased its capital to 6.814 billion RMB, marking a 28% increase [14] - 四川高端能源装备子基金 was established with a scale of 1.5 billion RMB [14] - 市北高新 invested 40 million RMB in a joint investment fund [14]